Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) have received an average rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $8.40.

SCYX has been the topic of a number of research analyst reports. Zacks Investment Research raised SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Wednesday, August 2nd. Roth Capital set a $9.00 target price on SCYNEXIS and gave the company a “buy” rating in a report on Monday, August 7th. HC Wainwright set a $14.00 target price on SCYNEXIS and gave the company a “buy” rating in a report on Wednesday, August 16th. ValuEngine downgraded SCYNEXIS from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 22nd. Finally, Guggenheim initiated coverage on SCYNEXIS in a report on Tuesday, October 24th. They issued a “buy” rating and a $6.00 target price on the stock.

A number of hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP lifted its holdings in SCYNEXIS by 17.1% in the third quarter. GSA Capital Partners LLP now owns 206,900 shares of the company’s stock valued at $499,000 after acquiring an additional 30,200 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of SCYNEXIS in the third quarter worth about $264,000. National Asset Management Inc. bought a new position in shares of SCYNEXIS in the second quarter worth about $551,000. DAFNA Capital Management LLC raised its stake in shares of SCYNEXIS by 32.7% in the second quarter. DAFNA Capital Management LLC now owns 506,900 shares of the company’s stock worth $907,000 after buying an additional 125,000 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of SCYNEXIS by 6.0% in the second quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock worth $1,554,000 after buying an additional 48,978 shares during the period. 30.45% of the stock is currently owned by institutional investors.

Shares of SCYNEXIS (NASDAQ SCYX) traded up $0.03 during trading hours on Monday, hitting $1.88. The stock had a trading volume of 45,989 shares, compared to its average volume of 159,851. The company has a debt-to-equity ratio of 0.43, a quick ratio of 7.30 and a current ratio of 7.30. SCYNEXIS has a 1 year low of $1.52 and a 1 year high of $4.04.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/scynexis-inc-scyx-receives-8-40-average-price-target-from-brokerages/1726315.html.

SCYNEXIS Company Profile

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Analyst Recommendations for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.